Three miRNA Signatures in Glioma: From Molecular Mechanisms to Potential Clinical Application

NCT06883214 | Recruiting

• 1 other identifier: RS1821/23
• Study Type: observational
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

Individual overexpression of the three miRNAs negatively affects cell viability and proliferation mainly in grade III IDH-wild type cells, while in higher grade cells, the effect is more pronounced when the entire signature is overexpressed, individual and combined overexpression of the signature members is able to determine a significant reduction in both migration and invasion. Therefore, ectopic expression of the miRNAs identified by us has a negative impact on cell viability, proliferation and apoptosis, but above all on migration and invasion.

Conditions

Glioma

Outcome Measures

Primary Outcomes (1)

• Dose-response curves

  Cellular sensitivity to radiotherapy and temozolamide will be assessed by dose-response curves in both IDH-wild type and IDH-mutated patient-derived cell lines and primary cells.

  36 months

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Tissue samples from patients with glioma

You may qualify if:

• histological diagnosis of glioma;
• no concomitant primary tumor;
• no metastatic disease;
• availability of surgical material/tissue;
• written informed consent.

You may not qualify if:

• histological diagnosis of non-glial tumor;
• patients with concomitant other solid tumors;
• metastatic disease;
• no surgical material/tissue available;
• HIV seropositivity.

Sponsors & Collaborators

• Regina Elena Cancer Institute: lead
• University of Roma La Sapienza: collaborator
• San Camillo Hospital, Rome: collaborator
• Fondazione Policlinico Universitario Agostino Gemelli IRCCS: collaborator
• Neuromed IRCCS: collaborator

Study Sites (1)

"Regina Elena" National Cancer Institute

Rome, 00144, Italy

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Tissue sample

MeSH Terms

Conditions

Glioma

Condition Hierarchy (Ancestors)

Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Central Study Contacts

Ana Belen Diaz, Doctor

CONTACT

06-52662522; anabelen.diaz@ifo.it

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 12, 2025
• First Posted: March 19, 2025
• Study Start: January 17, 2023
• Primary Completion (Estimated): January 17, 2027
• Study Completion (Estimated): January 17, 2027
• Last Updated: March 19, 2025

Record last verified: 2025-03

Locations

IT (1)